Wednesday, 21 Aug 2019

You are here

Filgotinib in Psoriatic Arthritis and Ankylosing Spondylitis

Another, new Janus kinase 1 (JAK1) inhibitor is out with impressive data - this time it’s filgotinib, demonstrating its efficacy and safety two separate clinical trials of patients with psoriatic arthritis (PsA) or ankylosing spondylitis (AS).

PSORIATIC ARTHRITIS

The EQUATOR trial was multicenter, phase 2 study oof 191 patients with active moderate-to-severe PsA. Patients continued their background csDMARDs and were randomized to filgotinib 200 mg or placebo orally once daily. The primary endpoint was the ACR20 response at 16 weeks.

Overall, an ACR20 response was seen in 80% of filgotinib patients but only 33% of the placebo patients (treatment difference 47% [95% CI 30·2–59·6], p<0·0001).

Safety signals were similar. The most common events were nasopharyngitis and headache. 

ANKYLOSING SPONDYLITIS

The TORTUGA trial was a multicenter, phase 2 trial, wherein active AS patients were randomized to receive filgotinib 200 mg or placebo orally daily for 12 weeks. The primary endpoint was the change in the ankylosing spondylitis disease activity score (ASDAS) at week 12. (Citation source: https://buff.ly/2KwhxN6)

A total of 116 AS patients were treated. The mean ASDAS change was greater (−1·47) in the filgotinib group compared with placebo (−0·57) treated patients (least squares mean difference between groups of −0·85 (95% CI −1·17 to −0·53; p<0·0001).

There were no deaths reported during the study. Other adverse events were minor and balanced between groups.

These trials suggest that JAK 1 inhibition with filgotinib is efficacious and safe for the treatment ankylosing spondylitis and psoriatic arthritis patients not responding to conventional therapies. 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Skyrizi Outduels Humira in Psoriasis

A head-to-head trial has shown that risankizumab was significantly superior to adalimumab in providing skin clearance (PASI90) in patients with moderate-to-severe plaque psoriasis, with no difference in safety signals between the two agents.

Biologic Therapy Improves Psoriasis and Reduces CV Inflammation

Psoriasis confers a significant risk of comorbidity, but is psoriasis associated with increased coronary inflammation and is this risk attenuated by biologic therapy? JAMA Cardiology has published a cohort study of 134 consecutive patients with moderate to severe psoriasis, showing that biologic therapy was associated with a significant decrease in coronary inflammation as assessed by perivascular fat attenuation index, a marker of coronary inflammation associated with cardiovascular outcomes. Patients not receiving biologic therapy had no change in perivascular fat attenuation index at 1 year.

Joint Surgery Rates Remain High in Psoriatic Arthritis

The incidence rate of joint surgery among patients with psoriatic arthritis (PsA) has remained persistently high, double that of the general population, according to a new Danish cohort study.

Fatigue is Driven by Inflammation, Pain, and Chronicity in Psoriatic Arthritis

Correlates with fatigue were assessed in psoriatic arthritis (PsA) patients in the DANBIO registry and found to be associated with  clinical inflammatory factors, disease duration, and chronic pain.

A toital of 2062 PsA patients in the Danish nationwide registry DANBIO were studied by cross-sectional survey from December 2013 to June 2014.

CAM Use is Common in Psoriasis

The July issue of the Journal of the American Academy of Dermatology reports that patients with psoriasis are frequent users of complementary and alternative medicines (CAMs) largely because of disatisfaction with traditional medications.

The National Psoriasis Foundation commissioned a survey of patients on CAMs use and patients' perceptions.

The survey was sent to 100,927 NPF members and 219 completed it.